Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Avelumab Program Rollover Study
NCT03815643 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Conditions Studied
Interventions
- DRUG Avelumab
Study Locations (20)
Ohio
- University of Cincinnati - PARENT — Cincinnati
- Oncology Hematology Care — Cincinnati
- Oncology/Hematology Care Clinical Trials, LLC — Cincinnati
- OSU - James Comprehensive Cancer Center — Columbus
California
- University of California Davis Health System - Comprehensive Cancer Center — Sacramento
- Providence Medical Foundation — Santa Rosa
- St Joseph Heritage Healthcare — Santa Rosa
South Carolina
- Medical University of South Carolina (MUSC) — Charleston
- Greenville Hospital System University Medical Center (ITOR) - Upstate Affiliate Organization — Greenville
Arizona
- HonorHealth Research Institute — Scottsdale
Arkansas
- Highlands Oncology Group — Fayetteville
Connecticut
- Norwalk Hospital - The Whittingham Cancer Center — Norwalk
Florida
- Hematology - Oncology Associates of the Treasure Coast - Hematology-Oncology Associates of Treasure Coast — Port Saint Lucie
Georgia
- Northwest Georgia Oncology Centers — Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2027-02-19 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815643
The ClinicalTrials.gov registry entry for NCT03815643 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention — of which Avelumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03815643 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Ohio, California, South Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03815643 about?
NCT03815643 is a clinical study titled "Avelumab Program Rollover Study". The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
What is the current status of trial NCT03815643?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2019-03-22. Estimated completion is 2027-02-19.
What conditions does trial NCT03815643 study?
This clinical trial studies the following conditions: Solid Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03815643?
The interventions under investigation include: Avelumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03815643?
This trial is sponsored by EMD Serono Research & Development Institute, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03815643 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.